Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9162350rdf:typepubmed:Citationlld:pubmed
pubmed-article:9162350lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:9162350lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9162350lifeskim:mentionsumls-concept:C0600139lld:lifeskim
pubmed-article:9162350lifeskim:mentionsumls-concept:C1282907lld:lifeskim
pubmed-article:9162350lifeskim:mentionsumls-concept:C0332305lld:lifeskim
pubmed-article:9162350pubmed:issue5 Suppllld:pubmed
pubmed-article:9162350pubmed:dateCreated1997-5-29lld:pubmed
pubmed-article:9162350pubmed:abstractTextLow stage and grade prostate cancer can be treated by radical prostatectomy, radiotherapy and expectant therapy. Preoperative evaluation with biopsy is in many cases unreliable to pathological stage and grade. In this study we considered 31 patients with prostate cancer, evaluated with directed ultrasound guided biopsy (15) or with sextant biopsy (16). Sextant biopsy showed better results. Grading was confirmed by radical prostatectomy specimen in 62.5%. The role of expectant therapy is then discussed.lld:pubmed
pubmed-article:9162350pubmed:languageitalld:pubmed
pubmed-article:9162350pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9162350pubmed:citationSubsetIMlld:pubmed
pubmed-article:9162350pubmed:statusMEDLINElld:pubmed
pubmed-article:9162350pubmed:monthDeclld:pubmed
pubmed-article:9162350pubmed:issn1124-3562lld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:PagliaruloAAlld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:LorussoAAlld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:CuratoloCClld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:LudovicoG MGMlld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:Giocoli...lld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:Cirillo...lld:pubmed
pubmed-article:9162350pubmed:authorpubmed-author:MaruccoE CEClld:pubmed
pubmed-article:9162350pubmed:issnTypePrintlld:pubmed
pubmed-article:9162350pubmed:volume68lld:pubmed
pubmed-article:9162350pubmed:ownerNLMlld:pubmed
pubmed-article:9162350pubmed:authorsCompleteYlld:pubmed
pubmed-article:9162350pubmed:pagination155-7lld:pubmed
pubmed-article:9162350pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:meshHeadingpubmed-meshheading:9162350-...lld:pubmed
pubmed-article:9162350pubmed:year1996lld:pubmed
pubmed-article:9162350pubmed:articleTitle[Role of expectant therapy in prostatic carcinoma of low grade and staging].lld:pubmed
pubmed-article:9162350pubmed:affiliationCattedra di Urologia, Università degli Studi di Bari.lld:pubmed
pubmed-article:9162350pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9162350pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9162350pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:9162350pubmed:publicationTypeControlled Clinical Triallld:pubmed